News

Conclusions from the 6th Pharmacoeconomics Section International Conference

The Value in Innovation in Decision Making

Dear colleagues,

Innovations drive increased spending in health care systems as new medicines tend to be priced higher than current standards. Financial stability, the main aim of the health system of CEE region, depends on two key challenges, which are how to best spend resources which are already in the system and the other challenge is should the health system have more or less money. To be relevant to decision making in the CEE region, HTA agencies must address these key challenges.

MEAs are one part of addressing financial stability of health systems in CEE region. But MEAs should be applied together with HTA, so they can start to address clinical and economic uncertainties and provide a transparent and timewise framework for deliberative decision-making. However, this is challenging at the moment with typically confidential arrangements between companies and payers, as well as a reluctance among companies to make decision making more transparent as seen for instance in Poland.

A lack of access to innovative health technologies is causing significant harm both in the region and globally, particularly in Serbia. However providing access to such technologies is politically and financially complex and challenging.

We look forward to welcoming you to our future Conferences.

With kind regards,
MSc Tanja Novakovic
Pharmacoeconomics Section President

"THE VALUE OF INNOVATION IN DECISION MAKING"


The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia (SFE SFUS) is organising its Sixth International Conference with the topic:
"THE VALUE OF INNOVATION IN DECISION MAKING", which will take place in Belgrade on 2nd June 2017, hotel Metropol, Serbia
Conference program will be proactive and it will represent unique event in Serbia and region.
(http://www.farmakoekonomija.org and http://www.farmacija.org/).
Main topics of the Conference are:
Managed Entry Agreements (MEA)
Link between MEA and Health Technology Assessment (HTA)
Access to personalised medicines, orphan drugs and high cost medicines
Role of patient registries in Access to medicines
The public economics consequences of health and investments in healthcare
The Conference program is intended for decision makers, makers of health policy design managers in health care institutions, employees of pharmaceutical companies (in the sectors of market access, pricing, health economics, regulation, marketing and sales), doctors and pharmacists who work in the public and private sectors. Participants of the Conference will have the opportunity to obtain new knowledge from world and local experts and exchange their experience and opinions.
Conference Participants Registration fees
till 25th March 2017From 25th March 2017
SFUS members 225 € 275 €
Others 300 € 350 €
Undergraduate students 100 € 150 €
Meet the experts dinner 50 € 50 €
Executive Organizer: SMART TRAVEL PCO, Njegoševa 72 a, Beograd, Phones: + 381 11 770 2184 Fax: + 381 11 244 7524, E- mail address: smarttravelpco4@smarttravelpco4.rs Web address: www.smarttravelpco4.rs
Dear Colleagues,

It is our great honour and pleasure to congratulate you on the jubilee of Pharmacoeconomics Section of the Pharmaceutical Association of Serbia, which marks 10 years of our section.
I wish you all continued success in our future work!

BB Soft informantor has published an interview where I discuss the challenges of health and pharmacoeconomics in the region, along with the development of the section, our activities and future plans.

With kind regards,
MSc Tanja Novakovic
Pharmacoeconomics Section President
Is Belgrade the New Berlin?
APRIL 6, 2017
Vogue
No city makes you feel more like a New Yorker than Belgrade. In Belgrade, people don’t walk, they amble; lunch spans the course of 3 or 4 hours; and drinks are sipped, never knocked back. Despite the slow pace of life, there’s still an unmistakable energy that bursts through the city.
Preliminary Program


The preliminary program for the conference "THE VALUE OF INNOVATION IN DECISION MAKING" is now available. Use the link above or access from the menu in the top right.
VI International SFE SFUS Conference
2nd June 2017, Belgrade, hotel Metropol, Serbia.

The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia (SFE SFUS) is organising its Sixth International Conference with the topic:
"THE VALUE OF INNOVATION IN DECISION MAKING"
Fifth International Conference - Speakers
9th and 10th of October 2015 Belgrade, hotel Metropol
SFE SFUS
Prof. dr Brian Godman PhD, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, UK; Karolinska Institute, Sweden

Wija Oortwijn PhD, Partner at ECORYS NL, The Netherlands

Krzysztof Landa MD, President at MedInvest Scanner Ltd M.I.S., Poland

Mark Parker MSc, Health Economics Unit, University of Liverpool Management School, UK

Angela Yu MSc, London School of Economics, UK

Timothy Johnston, Program Leader for Inclusive Growth and Human Development, Southeast Europe, Europe and Central Asia Region, World Bank

Dávid Dankó PhD, Managing Director at Ideas & Solutions, Hungary

Dr. Günter Harms, Market Access and Public Affairs Director, Shire, Germany

Vanesa Benkovic MSc, Senior HTA and health research consultant, Croatia

Bojan Trkulja MD, Managing Director at INOVIA, Serbia

Tanja Novakovic MSc Pharm, President of Pharmacoeconomics Section, Serbia, Representative of Chamber of Commerce and Industry of Serbia


Jovan Mihajlovic, MSc Pharm, Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy, University of Groningen, The Netherlands

Livio Garattini, Mario Negri Institute, Milano, Italija

Jakub Adamski, Arcana Institute, Poland

Alan Haycox, MSc, Health Economics Unit, University of Liverpool Management School, UK

Norbert Wilk, Arcana Institute, Poland

Neven Lovrinov, MSc Pharm, Terminal d.o.o., Croatia

ARE WE READY FOR BIOSIMILARS?
Belgrade, 28th April 2015, hotel Crowne Plaza
The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia
The objectives of the conference are:

• present the characteristics of biopharmaceutical medicines and biosimilars,

• understanding the nature of biopharmaceutical and biosimilar regulations,

• share clinical experience with biological medications and more generally

• exchanging experiences and knowledge with experts from the region and international stage.
Managed Introduction of new medicines
11 – 13 May 2015 - Warsaw, Poland
PIPERSKA workshop co-organised with the Agency for HTA & Tariff System in Poland and WHO Europe
This course is primarily intended for healthcare
professionals involved with enhancing the rational use
of medicines especially new medicines
Fifth Adriatic and Fourth Croatian Congress of Pharmacoeconomics and Outcomes Research
Šibenik, Croatia, from 23rd to 26th April 2015.
Section for Pharmacoeconomics and Outcomes Research of the Croatian Society for Clinical Pharmacology and Therapeutics, Croatian Medical Association
This year focus will be on the following subjects: 'The role and impact of pharmaceutical industry on the general economy in countries in the region' and 'The need to adapt the model for health technology assessment in countries with high risk of sustainability of healthcare financing in order to ensure transparency and competitiveness'.
PATIENTS REGISTERS IN ORDER TO IMPROVE THE QUALITY OF CARE AND REDUCE THE COSTS OF TREATMENT
5th of February 2015 Crowne Plaza Hotel, Belgrade, SERBIA
SFUS Pharmacoeconomics Section
The purpose of the Conference is to:
• Introduce and present the importance and value of patient registries,
• Introduce health outcomes and treatment outcomes reported by patients,
• Exchange experiences across the countries that used data of patients registers in the
pharmacoeconomic analysis
• Introduce the examples of special agreements (Risk sharing, Pay per Performance)
HTA for Healthcare Quality Assurance
December 15th-16th, 2014, Kraków, Poland
CEESTAHC 9th International Symposium Evidence-Based Health Care 2014